The Weill Cornell Medicine ? Rutgers New Jersey Medical School Clinical Trials Unit (WCM-NJMS CTU) will conduct National Institute of Allergy and Infectious Diseases (NIAID)-sponsored network studies of HIV treatment and HIV prevention; enroll participants from the diverse communities of the New York City (NYC)- Newark metropolitan area, the epicenter of the HIV epidemic in the U.S. -- home to 14% of Americans living with HIV; and contribute to the networks' scientific agendas. The unit consists of a central core facility and three clinical research sites (CRS). The WCM-NJMS CTU provides central research support to the three CRSs, including investigative and laboratory oversight, financial administration, quality assurance, training, and community engagement. The three CRSs, WCM-Uptown, WCM-Chelsea, and Rutgers NJMS, are located in different parts of the NYC-Newark metropolitan area and serve distinct, racially and ethnically diverse populations of people living with or at-risk for HIV. The WCM-Uptown CRS is located close to Harlem, with some neighborhoods demonstrating HIV seroprevalence rates of over 5%. The WCM-Chelsea CRS is located in Chelsea, with some neighborhoods demonstrating the highest seroprevalence rate in NYC of over 8%. The Rutgers NJMS CRS is located in the center of Newark, serving a predominately African American population with a high proportion of women, with some neighborhoods demonstrating an HIV seroprevalence rate of over 5%. WCM-NJMS CTU investigators are leaders in the field who are shaping the HIV treatment and HIV prevention research agendas. They are highly experienced with expertise in HIV cure strategies, antiretroviral drugs and treatment strategies, tuberculosis, and HIV comordibidities, including hepatitis and neurologic complications as well as HIV prevention strategies, including HIV pre-exposure prophylaxis (PrEP) and integrated strategies. Community engagement is a key strength of the WCM-NJMS CTU with both site-specific and joint Community Advisory Boards (CABs) and a strong record of effectively communicating study results back to the community. The CTU's three CRSs have successfully enrolled over 1000 participants into a wide variety of HIV treatment and prevention trials during the current grant cycle with outstanding retention and data quality. Furthermore, CTU investigators have made substantive scientific and leadership contributions to the networks. In summary, the WCM-NJMS CTU brings together a diverse group of recognized investigator leaders who will work with an experienced clinical research staff to conduct cutting-edge HIV treatment and HIV prevention studies in the NYC-Newark metropolitan areas.

Public Health Relevance

The New York City ? Newark metropolitan area is the area of the U.S. most affected with over 130,000 people living with HIV and over 2000 newly diagnosed with HIV each year. The WCM-NJMS CTU will conduct studies of HIV treatment and HIV prevention to advance the field. WCM-NJMS CTU investigators are key leaders in the field who are shaping the research agendas of the DAIDS networks.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Cogliano, Nancy A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Weill Medical College of Cornell University
Internal Medicine/Medicine
Schools of Medicine
New York
United States
Zip Code
MacBrayne, Christine E; Marks, Kristen M; Fierer, Daniel S et al. (2018) Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. J Antimicrob Chemother 73:2112-2119
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Figueroa, Dominique B; Madeen, Erin P; Tillotson, Joseph et al. (2018) Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells. AIDS Res Hum Retroviruses 34:421-429
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Hosseinipour, Mina C; Kang, Minhee; Krown, Susan E et al. (2018) As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clin Infect Dis 67:251-260
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Taiwo, Babafemi O; Zheng, Lu; Stefanescu, Andrei et al. (2018) ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Clin Infect Dis 66:1689-1697
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Wilkin, Timothy J; Chen, Huichao; Cespedes, Michelle S et al. (2018) A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis 67:1339-1346
Benson, Constance A; Andersen, Janet W; Macatangay, Bernard J C et al. (2018) Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. Clin Infect Dis 67:1712-1719

Showing the most recent 10 out of 130 publications